FY2024 EPS Estimates for Immunome Cut by Leerink Partnrs

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Leerink Partnrs dropped their FY2024 earnings estimates for shares of Immunome in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($2.23) for the year, down from their previous forecast of ($1.63). The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Leerink Partnrs also issued estimates for Immunome’s Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($4.36) EPS and FY2027 earnings at ($3.97) EPS.

Several other research analysts have also weighed in on IMNM. Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Finally, Stephens began coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Price Performance

Immunome stock opened at $9.39 on Monday. The company’s 50 day simple moving average is $12.91 and its 200 day simple moving average is $13.70. Immunome has a fifty-two week low of $6.93 and a fifty-two week high of $30.96. The firm has a market capitalization of $586.10 million, a price-to-earnings ratio of -1.16 and a beta of 1.82.

Insiders Place Their Bets

In other Immunome news, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Hedge funds have recently bought and sold shares of the stock. EntryPoint Capital LLC raised its holdings in Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after buying an additional 5,466 shares during the period. Quest Partners LLC acquired a new stake in shares of Immunome in the second quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Immunome in the second quarter valued at approximately $97,000. Arizona State Retirement System raised its holdings in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Immunome in the third quarter valued at approximately $219,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.